Tumor mutational burden (TMB) is a promising biomarker for predicting positive patient response to immune checkpoint inhibitors.
TMB measurements can be determined using genomic DNA extracted from FFPE-preserved tissue biopsy samples. However, assessment of TMB from a surrogate blood sample (liquid biopsy), referred to as blood TMB (bTMB), is an attractive alternative clinical diagnostic tool that would allow clinicians and patients to avoid the invasive challenge of tissue biopsies.
This poster from LGC SeraCare presents data supporting the use of blood tumor mutational burden (bTMB) reference materials that can aid in the development, validation, and quality control of circulating cell-free DNA assays used to determine TMB scores from blood samples.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences